ACE2-scFc protein therapeutic - United Biomedical
Latest Information Update: 28 Mar 2024
At a glance
- Originator United Biomedical
- Class Antivirals; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in Taiwan (Parenteral)
- 26 Feb 2020 United Biomedical files for patent protection for ACE2-scFc protein therapeutic and its manufacturing process
- 26 Feb 2020 Early research in COVID-2019-infections in Taiwan (Parenteral)
Development Overview
Introduction
An ACE2-scFc protein therapeutic is being developed as an antiviral therapy, for the treatment of COVID-2019 infections by United Biomedical. The company-developed ACE2-scFc protein competitively inhibits the entry of the virus into host cells, wherein the virus binds to it, instead of the ACE2 receptor. The ACE2-scFc protein replaces the neutralising antibody therapy taken from patients recovering from infection and is expected to have better efficacy and longer half-life for patients, relative to that conferred by the antibody. Additionally, the blocking effect of the protein on the virus remains unfazed by viral mutation. Early research is underway in Taiwan.
As at March 2024, no recent reports of development had been identified for research development in COVID-2019-infections in Taiwan (Parenteral).
Patent Information
In February 2020, United Biomedical reported that it has filed patent applications related to its products and associated manufacturing process details based on the biological information related to 2019-nCoV virus and its receptor ACE2 [1] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Antivirals, Proteins
- Mechanism of Action Undefined mechanism
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7E9 (All other viral vaccines)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | No development reported (Research) | Taiwan | Parenteral / unspecified | United Biomedical | 28 Mar 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| United Biomedical | Originator | USA |
| United Biomedical | Owner | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in Taiwan (Parenteral) Updated 28 Mar 2024 |
| 26 Feb 2020 | Patent Information | United Biomedical files for patent protection for ACE2-scFc protein therapeutic and its manufacturing process [1] Updated 04 Mar 2020 |
| 26 Feb 2020 | Phase Change | Early research in COVID-2019-infections in Taiwan (Parenteral) [1] Updated 04 Mar 2020 |
References
-
UBI Group's scientific research energy will tackle the human catastrophe caused by the new crown pneumonia virus.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG